[go: up one dir, main page]

AR071232A1 - Proteina hibrida usada como vacuna contra toxinas shiga de e. coli - Google Patents

Proteina hibrida usada como vacuna contra toxinas shiga de e. coli

Info

Publication number
AR071232A1
AR071232A1 ARP090101546A ARP090101546A AR071232A1 AR 071232 A1 AR071232 A1 AR 071232A1 AR P090101546 A ARP090101546 A AR P090101546A AR P090101546 A ARP090101546 A AR P090101546A AR 071232 A1 AR071232 A1 AR 071232A1
Authority
AR
Argentina
Prior art keywords
hybrid protein
protein
coli
plant cells
vaccine against
Prior art date
Application number
ARP090101546A
Other languages
English (en)
Inventor
Kazatoshi Sawada
Kazuya Yoshida
Takeshi Matsui
Original Assignee
Idemitsu Kosan Co
Nat Univ Corp Nara Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idemitsu Kosan Co, Nat Univ Corp Nara Inst filed Critical Idemitsu Kosan Co
Publication of AR071232A1 publication Critical patent/AR071232A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una proteína contra toxinas bacterianas, tal como una proteína de toxina de Shiga, que se produce en forma eficaz usando células vegetales. Las células vegetales se transforman usando una construccion de ADN que contiene ADN que codifica para una proteína híbrida en la que las proteínas de toxina bacteriana, tales como las proteínas de toxina de Shiga, se asocian en tándem a través de un péptido que tiene las siguientes características (A) y (B) para producir la proteína de toxina bacteriana en las células vegetales: (A) una cantidad de aminoácidos que es de entre 12 a 30; y (B) un contenido de prolina que es de entre 20 y 35%. Reivindicacion 3: La proteína híbrida de acuerdo con la reivindicacion 2, caracterizada porque el péptido tiene una secuencia de aminoácidos que está representada por SEQ ID N°: 2, 82, o 84.
ARP090101546A 2008-05-02 2009-04-29 Proteina hibrida usada como vacuna contra toxinas shiga de e. coli AR071232A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008120573 2008-05-02

Publications (1)

Publication Number Publication Date
AR071232A1 true AR071232A1 (es) 2010-06-02

Family

ID=41255098

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101546A AR071232A1 (es) 2008-05-02 2009-04-29 Proteina hibrida usada como vacuna contra toxinas shiga de e. coli

Country Status (11)

Country Link
US (2) US8846052B2 (es)
EP (2) EP2728004B1 (es)
JP (1) JP5360727B2 (es)
KR (1) KR101540496B1 (es)
CN (2) CN103626876B (es)
AR (1) AR071232A1 (es)
DK (2) DK2287300T3 (es)
ES (2) ES2686780T3 (es)
MX (1) MX2010011938A (es)
TW (1) TWI460270B (es)
WO (1) WO2009133882A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5360727B2 (ja) * 2008-05-02 2013-12-04 出光興産株式会社 細菌毒素ワクチン
JP5779577B2 (ja) * 2010-03-25 2015-09-16 国立大学法人富山大学 形質細胞同定及び単離用蛍光プローブ並びにこのプローブを用いた形質細胞の同定又は単離方法
JP5641205B2 (ja) * 2010-07-13 2014-12-17 出光興産株式会社 糖鎖修飾が抑制された改変Ｓｔｘ２ｅタンパク質
KR20140032394A (ko) 2011-03-30 2014-03-14 내셔날 유니버시티 코포레이션 유니버시티 오브 토야마 형질 세포 또는 형질아 세포의 선택 방법, 목적 항원 특이적인 항체의 제조 방법, 신규 단일 클론 항체
ES2713962T3 (es) * 2012-10-22 2019-05-24 Km Biologics Co Ltd Vacuna para prevenir la enfermedad de edema porcino
KR20160089466A (ko) 2013-11-26 2016-07-27 이데미쓰 고산 가부시키가이샤 대장균증용 백신
KR20160089412A (ko) 2013-11-26 2016-07-27 이데미쓰 고산 가부시키가이샤 대장균성 설사증의 예방
US20170305974A1 (en) * 2014-08-08 2017-10-26 Idemitsu Kosan Co., Ltd. Agent for controlling porcine reproductive and respiratory syndrome
WO2017094793A1 (ja) 2015-11-30 2017-06-08 出光興産株式会社 免疫原性が増強されたワクチン抗原
KR20180091098A (ko) 2015-12-28 2018-08-14 이데미쓰 고산 가부시키가이샤 펩티드 태그 및 그것을 포함하는 태그 부가 단백질
JPWO2017217460A1 (ja) * 2016-06-15 2019-04-04 出光興産株式会社 ペプチドリンカーで連結された２以上のタンパク質を含む融合タンパク質
JPWO2018225662A1 (ja) * 2017-06-07 2020-04-09 出光興産株式会社 自然免疫増強剤
CN112639103A (zh) * 2018-08-31 2021-04-09 出光兴产株式会社 利用肽标签的蛋白质可溶性表达

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0433372B1 (en) 1988-09-06 2002-06-12 Washington University Oral immunization by transgenic plants
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
EP0863211A1 (en) * 1992-07-31 1998-09-09 Medeva Holdings B.V. Expression of recombinant fusion proteins in attenuated bacteria
WO1996012801A1 (en) 1994-10-24 1996-05-02 The Texas A & M University System Oral immunization with transgenic plants
DE69736226T2 (de) 1996-04-19 2006-11-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren
BR9916515A (pt) 1998-12-22 2001-11-06 Thompson Boyce Plant Res Polinucleotìdeo, vetor de expressão, células de e. coli e de agrobacterium tumefaciens transformadas com o vetor de expressão, célula de planta transgênica, semente de planta transgênica, célula eucariótica transgênica, composição imunogênica, método de evocar uma resposta imune em um animal ou ser humano, planta transgênica, e, adjuvante
WO2001089456A2 (en) * 2000-05-19 2001-11-29 The Administrators Of The Tulane Educational Fund Hybrid lt-a/ct-b holotoxin for use as an adjuvant
JP4627879B2 (ja) 2000-12-28 2011-02-09 国立大学法人 奈良先端科学技術大学院大学 植物細胞において遺伝子の高発現能を有する５’−非翻訳領域配列
US7807184B2 (en) * 2003-07-21 2010-10-05 Interuet International B.V. Hybrid Shiga-like toxin
CN101016332B (zh) * 2007-03-07 2010-12-01 中国人民解放军军事医学科学院微生物流行病研究所 一种抑制志贺毒素的短肽及其用途
WO2009004842A1 (ja) 2007-07-03 2009-01-08 Idemitsu Kosan Co., Ltd. ブタ浮腫病ワクチン
JP5360727B2 (ja) * 2008-05-02 2013-12-04 出光興産株式会社 細菌毒素ワクチン

Also Published As

Publication number Publication date
JP5360727B2 (ja) 2013-12-04
EP2287300B1 (en) 2018-06-27
DK2728004T3 (en) 2018-11-05
KR20110009197A (ko) 2011-01-27
EP2728004A3 (en) 2014-07-23
ES2686780T3 (es) 2018-10-19
US20150133635A1 (en) 2015-05-14
CN103626876A (zh) 2014-03-12
EP2728004A2 (en) 2014-05-07
CN102016034B (zh) 2014-11-05
EP2287300A4 (en) 2011-06-22
ES2691985T3 (es) 2018-11-29
TWI460270B (zh) 2014-11-11
CN102016034A (zh) 2011-04-13
KR101540496B1 (ko) 2015-08-25
US8846052B2 (en) 2014-09-30
MX2010011938A (es) 2010-12-01
CN103626876B (zh) 2016-09-14
JPWO2009133882A1 (ja) 2011-09-01
EP2728004B1 (en) 2018-08-08
DK2287300T3 (en) 2018-09-17
US20110231960A1 (en) 2011-09-22
TW201005093A (en) 2010-02-01
EP2287300A1 (en) 2011-02-23
WO2009133882A1 (ja) 2009-11-05

Similar Documents

Publication Publication Date Title
AR071232A1 (es) Proteina hibrida usada como vacuna contra toxinas shiga de e. coli
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
AR075029A1 (es) Metodo para producir una proteina o un peptido fisiologicamente activo usando un fragmento de inmunoglobulina
MX348360B (es) Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas.
MX2011003502A (es) Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
EA201001435A1 (ru) Клетка, ферментирующая сахар-пентозу
MY167231A (en) Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same
NZ595500A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
MX2014011459A (es) Proteinas nutritivas cargadas y metodos.
EA201300054A1 (ru) Полипептид, обладающий активностью бета-глюкозидазы, и его применение
BR112014001909A2 (pt) gene da toxina axmi270 e métodos para a sua utilização
AR075634A1 (es) Proteinas pesticidas y metodos de uso de las mismas
ES2688623T3 (es) Proteínas de fusión que se unen a factores de crecimiento
EA201001881A1 (ru) Пролинспецифичная протеаза из penicillium chrysogenum
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
PE20201067A1 (es) Anticuerpos anti-csf 1r
RU2011154363A (ru) Комбинации клад rrgb пневмококков
PE20090483A1 (es) Vectores para la expresion multiple de genes
BR112014022034A2 (pt) gene da toxina axmi335 de bacillus thuringiensis e métodos para a sua utilização
NZ601488A (en) Immunogenic proteins and compositions
EA201300056A1 (ru) Полипептид с активностью ацетилксиланэстеразы и его применения
HK1206763A1 (en) Charged nutritive fragments, proteins and methods

Legal Events

Date Code Title Description
FB Suspension of granting procedure